Literature DB >> 10602512

Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice.

A Elson1.   

Abstract

Accurate phosphorylation of tyrosine residues in proteins plays a central role in regulation of cellular function. Although connections between aberrant tyrosine kinase activity and malignancy are well-established, significantly less is known about the roles of protein tyrosine phosphatases (PTPases) in tumorigenesis. We have previously shown that the transmembranal form of PTPase Epsilon (PTPepsilon) is upregulated in mouse mammary tumors initiated specifically by ras or neu, suggesting that PTPepsilon may play a role in transformation by these two oncogenes. In order to test this notion in vivo, we created transgenic mice that express elevated levels of PTPepsilon in their mammary epithelium by use of the MMTV promoter/enhancer. Following several cycles of pregnancy female MMTV-PTPepsilon mice uniformly developed pronounced and persistent mammary hyperplasia which was accompanied by residual milk production. Solitary mammary tumors were often detected secondary to mammary hyperplasia. The sporadic nature of the tumors, the long latency period prior to their development, and low levels of transgene expression in the tumors indicate that PTPepsilon provides a necessary, but insufficient, signal for oncogenesis. The results provide genetic evidence that PTPepsilon plays an accessory role in production of mammary tumors in a manner consistent with its upregulation in mammary tumors induced by ras or neu.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602512     DOI: 10.1038/sj.onc.1203098

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Dimerization in vivo and inhibition of the nonreceptor form of protein tyrosine phosphatase epsilon.

Authors:  Hila Toledano-Katchalski; Zohar Tiran; Tal Sines; Gidi Shani; Shira Granot-Attas; Jeroen den Hertog; Ari Elson
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

Review 2.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

3.  Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells.

Authors:  Caroline E Nunes-Xavier; Ari Elson; Rafael Pulido
Journal:  J Biol Chem       Date:  2011-11-23       Impact factor: 5.157

4.  Hypomyelination and increased activity of voltage-gated K(+) channels in mice lacking protein tyrosine phosphatase epsilon.

Authors:  A Peretz; H Gil-Henn; A Sobko; V Shinder; B Attali; A Elson
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

5.  High-resolution crystal structures of the D1 and D2 domains of protein tyrosine phosphatase epsilon for structure-based drug design.

Authors:  George T Lountos; Sreejith Raran-Kurussi; Bryan M Zhao; Beverly K Dyas; Terrence R Burke; Robert G Ulrich; David S Waugh
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-10-02       Impact factor: 7.652

Review 6.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

7.  Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo.

Authors:  Riccardo Chiusaroli; Hilla Knobler; Chen Luxenburg; Archana Sanjay; Shira Granot-Attas; Zohar Tiran; Tsuyoshi Miyazaki; Alon Harmelin; Roland Baron; Ari Elson
Journal:  Mol Biol Cell       Date:  2003-10-03       Impact factor: 4.138

8.  Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.

Authors:  Jinyu Li; Raffaella Sordella; Scott Powers
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

9.  miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE.

Authors:  Bingqing Chen; Zhibin Liao; Yongqiang Qi; Hongwei Zhang; Chen Su; Huifang Liang; Bixiang Zhang; Xiaoping Chen
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.